Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
NCT00114231Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2006
- Primary completion
- Dec 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: 3-Year Disease-free Survival. Started May 2006; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00114231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114231.